Logo
Revolax Deep

Revolax Deep

Revolax

Dermal filler (medical device)
  • CE Marked Class III medical device for dermal implantation
  • Manufactured under ISO 13485 Compliant quality management system for medical devices
  • Produced according to Good Manufacturing Practice (GMP) standards
  • Non Animal Based hyaluronic acid obtained via bio Fermentation and extensively purified
  • Biodegradable, monophasic HA filler in compliance with relevant EU/UK medical device regulations
Monophasic cross-linked hyaluronic acid dermal filler for mid-to-deep wrinkles and facial contouring

Description

Revolax Deep with Lidocaine (1 x 1.1ml) is a CE-marked, monophasic cross-linked hyaluronic acid dermal filler developed by Across Co., Ltd. in South Korea for the correction of deep wrinkles and facial volume loss. Using high-purity, non-animal HA at 24 mg/ml combined with 0.3% lidocaine, it is designed for mid-to-deep dermis or subcutaneous implantation to treat deep nasolabial folds and other pronounced wrinkles, as well as for non-surgical rhinoplasty and augmentation of cheeks, chin and lips. Its highly structured, cohesive gel with high viscoelasticity allows for excellent shape retention, predictable volume distribution and natural-looking, long-lasting results, typically lasting 12–18 months.

Bnefits

  • Thicker, longer-lasting gel than Revolax Fine, providing stronger lift and support for deeper tissues
  • High viscoelasticity ensures excellent shape retention and controlled volume distribution in the tissue
  • Effective correction of deep wrinkles and nasolabial folds for a more youthful appearance
  • Suitable for non-surgical rhinoplasty and augmentation of cheeks, chin and lips
  • Contains 0.3% lidocaine for increased patient comfort and reduced injection pain
  • Non-animal-based, highly purified hyaluronic acid with low risk of immunogenic reaction
  • Monophasic, cohesive gel structure designed to minimise migration and provide stable, natural results
  • CE-marked Class III medical device compliant with European/UK safety regulations
  • Long duration of results, usually 12–18 months depending on patient and treatment area

Indications

  • Deep wrinkles and folds
  • Deep nasolabial folds (smile lines)
  • Moderate-to-severe facial wrinkles in mid-to-deep dermis
  • Non-surgical rhinoplasty (nose bridge and tip contouring, dorsal hump correction)
  • Cheek augmentation and contouring
  • Chin augmentation and definition
  • Lip augmentation and volumisation
  • General deep tissue volume restoration and facial contouring in suitable patients

Composition

  • Cross-linked sodium hyaluronate (hyaluronic acid) 24 mg/ml
  • Lidocaine hydrochloride 0.3% (for local anaesthetic effect)
  • Non-animal, bio-fermentation-derived hyaluronic acid
  • Physiological buffer solution and standard injectable excipients
  • Biodegradable, monophasic HA gel cross-linked with a standard HA cross-linking agent (e.g. BDDE) in minimal residual amounts after purification

Formulation

  • Monophasic, highly cohesive cross-linked hyaluronic acid gel
  • High viscoelasticity (complex viscosity around 160 MPa as listed by some distributors)
  • Thicker and more durable gel than Revolax Fine, but less viscous than Revolax Sub-Q
  • Designed for mid-to-deep dermis and subcutaneous tissue injection
  • Non-animal-based, biodegradable HA with lidocaine for improved comfort

Packaging

  • Box containing 1 x 1.1 ml prefilled glass syringe of Revolax Deep with Lidocaine
  • Typically supplied with 2 x 27G needles (some distributors describe pack as 1 x 27G needle included)
  • Instructions leaflet / Instructions for Use (IFU)
  • CE-marked Class III labelling with traceability stickers for medical records

Usage

  • For professional use only; must be administered by suitably trained and qualified medical or aesthetic practitioners.
  • Intended injection depth: mid-to-deep dermis or subcutaneous layer depending on indication and anatomical location.
  • Recommended treatment areas include deep nasolabial folds, other deep facial folds, cheeks, chin, lips and nose (non-surgical rhinoplasty).
  • Use strict aseptic technique, thoroughly disinfecting the treatment area and maintaining sterility of the syringe and needles.
  • Attach a 27G needle (or as supplied/clinically indicated) and expel any air from the syringe prior to injection.
  • Inject slowly with minimal pressure using appropriate techniques such as linear threading, serial puncture, fanning or small bolus injections, tailored to the area and depth.
  • Avoid intravascular injection; aspirate according to clinic protocol and continuously monitor for any signs of vascular compromise during the procedure.
  • After injection, gently massage or mould the treated area if needed to distribute the filler evenly and refine contour.
  • Advise patients to avoid makeup on the treated areas for several hours and to avoid alcohol, strenuous exercise, and exposure to extreme heat or cold (e.g. saunas, sunbeds) for at least 24 hours or as per clinic protocol.
  • Always refer to and follow the official Instructions for Use (IFU) supplied with the product for complete details on indications, techniques, precautions and aftercare.

Contraindications

  • Known allergy or hypersensitivity to hyaluronic acid, lidocaine or any of the excipients in the product
  • History of severe allergies or anaphylactic reactions unless fully evaluated and cleared by a physician
  • Active skin infections or inflammatory conditions at or near the intended injection site (e.g. herpes simplex, cellulitis, severe acne, dermatitis)
  • Tendency to develop hypertrophic or keloid scars
  • Pregnancy or breastfeeding
  • Ongoing systemic antibiotic therapy or other acute systemic infection (as noted by some distributors)
  • Autoimmune diseases or significant immunosuppression unless the risk–benefit has been individually assessed by the treating clinician
  • Patients under 18 years of age
  • Planned injection directly into blood vessels or in high-risk vascular regions without appropriate expertise and safety measures

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, tenderness, pain, itching, bruising or slight bleeding
  • Temporary lumps, papules, nodules or contour irregularities in the treated area, which may resolve spontaneously or require gentle massage or corrective management
  • Localised infection or abscess formation if aseptic technique is not strictly adhered to
  • Immediate or delayed hypersensitivity or inflammatory reactions including persistent swelling, erythema, induration or pruritus
  • Very rare but serious complications typical of HA-based fillers, including vascular occlusion, tissue ischemia or necrosis, and visual disturbances or blindness if filler is inadvertently injected into an artery; these require immediate emergency management
  • Any persistent, unusual or severe adverse effect should be promptly assessed and treated by an appropriately qualified medical professional

Storage Conditions

  • Store at 2–25 °C as indicated by the manufacturer.
  • Do not freeze.
  • Protect from direct sunlight and excessive heat.
  • Keep the syringe in its original sterile blister and outer carton until use to maintain sterility and traceability.
  • Do not use the product after the expiry date or if the packaging, blister or syringe appears damaged or previously opened.
  • Keep out of the reach of children.

Duration

Most sources report that Revolax Deep with Lidocaine provides results lasting approximately 12\u201318 months, depending on treatment area, patient metabolism, skin condition, injection technique and lifestyle factors.

Onset

Volumising and wrinkle-correcting effects are visible immediately after injection, with final aesthetic results becoming evident once initial swelling or redness subsides over the following days.

Browse more Dermal filler (medical device)

Top Treatments

Top Cities in the UK